plant procedures which are associated with high treatmentrelated morbidity and mortality. 1 However, immunologic graft-versus-leukemia (GVL) effects, 2 which play a major Thirty-two adults (median age 36 years) with leukemia (15 AML, eight CML, six ALL, three CLL) persisting role in long-term control of minimal residual disease and cure after allogeneic BMT, have been exploited or relapsing 1-40 months (median 4) after allogeneic BMT (20 matched siblings, eight unrelated, four family successfully to treat relapsed leukemia after allogeneic transplantation.
1
In most cases, effective GVL has been associated with objective response. Nine patients died due to toxicity and 10 due to progressive disease. Thirteen patients are clinically detectable graft-versus-host disease (GVHD), although there is evidence to show that a low dose of donor alive 4-58 months (median 14) after immunotherapy; 12 in remission (five AML, four chronic phase CML, cells can induce remission of chronic myeloid leukemia (CML) relapsing after T cell-depleted BMT without one ALL, one accelerated phase CML, one CLL) and one with progressive disease (accelerated phase CML).
GVHD. 14 Additionally, whether immunotherapy is effective in the treatment of relapsed acute lymphoblastic Eleven of 13 patients who are alive had GVHD compared with six of 19 who died (P = 0.005, Fisher's exact leukemia (ALL) is controversial. 15 We have attempted to induce GVHD and long-term test). We conclude that with the exception of CML in myeloid blast crisis, immunotherapy is active in most remission of disease by adoptive immunotherapy and/or abrupt cessation of cyclosporine in 32 adult patients with types of acute and chronic leukemia relapsing after allogeneic BMT. It is associated with considerable toxicity.
acute or chronic leukemia relapsing after allogeneic BMT.
Ten of these patients with acute leukemia and two with Clinically obvious GVHD, especially chronic GVHD, results in a higher probability of survival.
chronic lymphocytic leukemia/prolymphocytic leukemia (CLL/PLL) have been reported previously.
1,12
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Patients and methods
Between July 1991 and September 1996, 32 adult patients The prognosis of patients with leukemia who relapse after with acute (n = 21) or chronic (n = 11) leukemia relapsing allogeneic blood or marrow transplantation (BMT) is gener-(n = 25) or persisting (n = 7) after allogeneic BMT ally poor with conventional therapy. A small proportion of underwent immune manipulation to induce GVHD and patients with acute leukemia are eligible for second trans-GVL at the Royal Marsden Hospital. Immunotherapy was used only sporadically in 1991 (n = 1), 1992 (n = 1) and 1993 (n = 3), but was offered to the majority of patients The basic plan of immunotherapy consisted of cessation of immunosuppression with or without infusion of donor cells and administration of immunomodulating cytokines blinded marrow/blood from their siblings, 18 the frozen back-up donor product, the identity of which still remains (interferon-␣2b and interleukin-2); with added chemotherapy in patients with acute leukemia if needed. Figure  coded , was infused as immunotherapy (the third had discontinuation of cyclosporine as the only intervention). For 1 shows the general scheme according to which the type of immune manipulation used was determined in patients the remaining patients transplanted using marrow with or without blood from matched sibling or mismatched family with acute leukemia. Chemotherapy was not administered to CML patients except hydroxyurea as required to control donors (n = 13), G-CSF-mobilized donor cells were harvested by leukapheresis. Donors received 5-16 g/kg Gthe counts prior to immunotherapy. Also, interferon was not routinely used for CML patients in chronic phase.
CSF (median 5) for 4 or 6 days, and two or four aphereses were performed on consecutive days starting on day 4. Acute GVHD was treated when it was life-threatening (grade III with complicating medical problems or grade IV)
Cells from two collections were infused into patients, and any additional collections were cryopreserved for possible and chronic GVHD was treated when it became extensive; in any case, only if the underlying malignancy was in future use. This contained 2.6-9.2 × 10 8 nucleated cells (median 5.8), and where assayed, 1.6-7.3 × 10 6 CD34 + remission. All patients and donors gave informed consent for the treatment. cells (median 3.7) and 0.3-2.2 × 10 8 CD3 + T cells (median 1.6) per kg patient weight.
Donor leukocytes
Interferon-␣2b and interleukin-2 In the first patient receiving donor leukocytes from a sibling donor, the cells were collected by a single leukapheresis in Interferon was usually started at the dose of 1 million units per day subcutaneously, and then increased as tolerated the basal state. The same procedure was followed for all patients receiving cells from unrelated donors (n = 6).
symptomatically to 3-5 million units three to seven times a week. The frequency of administration was changed if There was no minimum target set for collection, with an attempt to harvest the maximum number of cells. The numrequired to control the symptoms. All patients had severe systemic adverse reactions (influenza-like symptoms, nauber of nucleated cells infused was 0.13-3.6 × 10 8 (median 2.4). The number of CD3 + cells in the collections was not sea, loss of appetite, diarrhea) to interferon which could be partially controlled with analgesics and antipyretics. The routinely assayed.
For two of the three patients relapsing after receiving duration of interferon therapy was 3-30 weeks (median 6). Excludes three T cell-depleted transplant recipients in whom cyclosporine
Response was defined as at least 50% reduction in measurwas being administered to prevent graft rejection rather than GVHD.
able disease (usually percent blasts in the marrow), and
Cyclosporine was discontinued concomitantly with donor leukocyte complete remission was defined as disappearance of all infusions in all three.
measurable disease. Normalization of blood counts was not a requirement for defining remissions because pancytopenia related to GVHD or donor leukocyte infusions was Toxicity anticipated in a proportion of the patients.
Nine patients (28%) died of causes related to the therapy: GVHD (n = 3), interstitial pneumonitis (n = 2), cytomegaloAssessment of GVHD virus pneumonitis (n = 1), multiorgan failure (n = 1), renal failure (n = 1), and intracerebral hemorrhage after a fall (n = GVHD was diagnosed on the basis of the typical clinical picture, although skin, rectal or liver biopsies were obtained 1). Predictable transient myelosuppression with subsequent hematologic recovery occurred in patients receiving chemoin equivocal cases. It was labeled acute or chronic depending upon the clinical picture rather than on the basis therapy, but prolonged pancytopenia or bone marrow aplasia requiring G-CSF administration or donor marrow of a 100-day period following immunotherapy, and was graded according to standard criteria. 19, 20 infusion was not seen in any patient.
GVHD Statistical analysis
All data are current as of 30 November 1996. Adequate Seventeen patients (53%) developed acute (n = 5), acute followed by extensive chronic (n = 1), or de novo chronic follow-up data were available on all patients except one patient with CML who was lost to follow-up 6 months ago (n = 11, seven extensive) GVHD. The clinical manifestations of chronic GVHD seen after immunotherapy were when she had progressive chronic hepatic GVHD. All patients were censored at the last follow-up, and death due similar to those seen after BMT, except that abnormalities of liver function (usually elevated alkaline phosphatase to any cause was plotted as an event (Figure 2) . with some hyperbilirubinemia) were almost universal. The use of interferon and/or interleukin-2 was not associated with more severe GVHD or risk of toxic death. The interval Results between transplant and immunotherapy was not correlated with the probability of development of GVHD. Table 3 shows the mode of immunotherapy employed. None of the patients had active GVHD at the time of immuEleven of 13 patients who are alive had GVHD compared with six of 19 who died (P = 0.005, Fisher's exact notherapy. A number of patients received more than one type of therapy simultaneously or sequentially. test). Four of 13 non-responders had GVHD compared with 13 of 19 responders (P 0= 0.07, Fisher's exact test).
Response and survival
Patients dying within 3 weeks of commencing immunotherapy (n = 3, two dying due to treatment-related toxicity and one due to progressive disease) were considered inevaluable for response. Ten patients showed no response to firstline therapy, four of whom received further therapy as outlined in Figure 1 . However, eight died of progressive disease, one died of toxicity, and one is alive with disease (patient 13, Table 4 ). Nineteen patients had an objective response to therapy. Table 2 shows response by disease and stage. Six of 19 responding patients relapsed again at 1.5-25 months (median 5); two are alive and well after further immunotherapy (Table 4) , three died of treatment-related toxicity, and one died of progressive disease. The latter limited chronic GVHD developed following immunother- This resulted in GVHD in six patients, five of whom attained CR. Three of the latter are alive (ALL, CML-AP, responding patients died of toxicity in remission.
Of the two relapsing patients who are still alive, one did CML-CP) and two died of GVHD (CLL and PLL). None of the four recipients of mismatched family transso when interferon was discontinued upon development of limited chronic GVHD. The disease remitted promptly plants, four of nine patients transplanted from unrelated donors, and nine of 19 matched sibling graft recipients are when interferon was reinstituted, and has remained under control despite stopping the interferon upon development alive (P = NS). of extensive chronic GVHD (patient 3, Table 4 ). 21 The other patient relapsed 2 years after the original therapy, and responded to chemotherapy followed by donor leukocytes Discussion (patient 2, Table 4 ).
Thirteen patients were alive at the last follow-up 4-58 Our data show that immunotherapy can result in prolonged remission of leukemia relapsing after allogeneic BMT in months (median 14) after immunotherapy (Table 4 ) and 4-103 months (median 14) after disease recurrence. The actuapproximately one-third of patients. In our experience, the treatment is effective in all types of leukemia except arial probability of survival for the entire group at 1 year is 38% (Figure 2) . The seven surviving patients with extenmyeloid blast crisis of CML. Although the treatmentrelated mortality is not as high as with second transplants, 1 sive chronic GVHD are on immunosuppression. Ten of 12 patients alive without disease are in continuous remission it is still substantial. The incidence of GVHD, especially extensive chronic GVHD, is high and contributes to poor following first-line immunotherapy.
Three of the six patients with a prior history of GVHD performance status following successful therapy. Although the algorithm outlined in Figure 1 is a practical responded compared with 16 of 26 with no previous GVHD (P = NS). The amount of disease at the onset of therapy approach, especially for initiating treatment, all 12 diseasefree survivors had responded to the first treatment they was also not predictive of response: In the entire group, 11 of 17 patients with Ͻ50% malignant cells responded received. None of the patients who received second-line immunotherapy after failing to respond to first-line therapy compared with eight of 15 with у50% (P = NS). Among patients with acute leukemia, eight of 13 patients with attained remission, and all died of disease or toxicity. Therefore, selection of optimum therapy at the outset is Ͻ50% malignant cells responded compared with three of eight with у50% (P = NS).
probably important. On the other hand, patients who respond to initial immunotherapy but then go on to relapse Abrupt cessation or rapid tapering of cyclosporine was the only therapy in nine patients (two each ALL and AML, at a later date may respond to further therapy (especially patients 2 and 3 in Table 4 ). Because of this, it is possible one each CML-CP, CML-AP, CML-BC, CLL and PLL).
that it is the inherent sensitivity of the disease which deterhas been done using graded increments of T cells after T cell-depleted transplants 26 or, inadvertently, with adminismines response rather than the first-line or second-line approach. 21 tration of post-allograft interferon to prevent viral infections. 27 We have seen a correlation between poor lymphoDespite the complex nature of the treatment in some patients, three of the survivors are alive after GVHD cyte recovery in the early stages after BMT for first remission AML and an increased risk of relapse. 28 It may induced by abrupt cessation of cyclosporine eradicated residual disease. Thus, withdrawal of immunosuppression be possible to identify such groups of patients depending upon the underlying disease and conditioning regimen, and is a simple and effective way to manage early relapse in patients with a small amount of recurrent disease. The risk infuse donor cells, abbreviate immunosuppression, or administer cytokines early after BMT to enhance immunoof explosive GVHD must be carefully weighed before this is done, especially where the tempo of disease response is logic GVL effects. slow following the transplant. 12 Whether immunotherapy is effective in relapsed ALL or not is a controversial issue.
11, 15 The very first patient ever Acknowledgments treated with donor leukocyte infusions had ALL, and he This work was supported by the Bud Flanagan Leukaemia Fund, was reported to be alive and well at the last follow up the Cancer Research Campaign, and the Leukaemia Research almost 9 years after therapy. 15 However, the EBMT group Fund. reported no response to immunotherapy in ALL. 11 Two of the six patients with ALL in this group responded, and one is alive (the other died of GVHD). We have previously References reported a pediatric patient with Philadelphia chromosomepositive ALL (not included in this report but described 1 Mehta J, Powles R, Treleaven J et al. Outcome of acute leukebriefly elsewhere 22, 23 ) who responded to donor leukocytes. immune reactions in elimination of residual disease. In
